Funding for this research was provided by:
Physicians' Services Incorporated Foundation
University of Toronto Dean's Fund
Text and Data Mining valid from 2018-11-26
Received: 21 November 2017
Accepted: 30 October 2018
First Online: 26 November 2018
Ethics approval and consent to participate
: The informed consent process was conducted in accordance with the Tri Council Policy Statement, the Declaration of Helsinki, and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)–Good Clinical Practice (GCP) guidelines and institutional policy. This study was approved by the Holland Bloorview Research Ethics Board. Ethics committee reference number (research ethics board project number): 10-153.
: Not applicable
: Dr. Evdokia Anagnostou has received consultation fees from Roche and Takeda; industry funding from SynapDx and Sanofi-Aventis; royalties from APPI and Springer International Publishing; editorial honorarium from Wiley; and other funding from the Canadian Institutes of Health Research, the Ontario Brain Institute, the Department of Defense, the National Institutes of Health (NIH), Brain Canada, Autism Speaks, the National Centers of Excellence, and Physician Services Incorporated.Dr. Jane A. Foster has had work supported by Ontario Brain Institute (OBI) Grant Nos. NSERC (RGPIN-312435-12) and NSERC RTI (EQPEQ407645-2011) as well as an infrastructure grant from the Canada Foundation for Innovation and the Ontario Innovation Trust.The remaining authors have no potential competing interests to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.